Utilizing Isolate Of Tissue Or Organ As Binding Agent Patents (Class 436/503)
-
Patent number: 7785810Abstract: The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipedidyl peptidase IV (DPPIV)] expressed on the surface of metastasizing cancer cells.Type: GrantFiled: August 28, 2001Date of Patent: August 31, 2010Assignee: The Research Foundation of State University of New YorkInventor: Wen-Tien Chen
-
Patent number: 7776538Abstract: Disclosed is useful means for the therapy or diagnosis of a mental disorder. A method for screening for a compound which is effective for a mental disorder, comprising the steps of (1) providing a cell capable of expressing a gene (target gene) selected from the group consisting of a gene having the nucleotide sequence depicted in SEQ ID NO:1, a gene having the nucleotide sequence depicted in SEQ ID NO:2, a gene having the nucleotide sequence depicted in SEQ ID NO:3 and genes homologous to these genes; (2) exposing the cell to a compound to be tested; (3) determining the amount of a product of the target gene expressed in the cell after the exposure to the compound; and (4) determining the change in amount of the product of the target gene under the influence of exposure to the compound.Type: GrantFiled: February 24, 2006Date of Patent: August 17, 2010Assignee: National University Corporation Nagoya UniversityInventors: Atsumi Nitta, Minae Niwa, Toshitaka Nabeshima
-
Patent number: 7749695Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.Type: GrantFiled: March 2, 2004Date of Patent: July 6, 2010Inventors: Alexander Abbas, Sarah Bodary, Hilary Clark, P Mickey Williams, Thomas D Wu
-
Patent number: 7745127Abstract: The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.Type: GrantFiled: July 18, 2005Date of Patent: June 29, 2010Assignee: Oryzon Genomics, S.A.Inventors: Tamara Maes, Carlos Buesa Arjol, Marta Barrachina Castillo, Isidro Ferrer Abizanda
-
Patent number: 7718384Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: GrantFiled: June 20, 2008Date of Patent: May 18, 2010Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7709216Abstract: Provided herein are methods relating to inhibition of PUMA function for preventing or reducing myocardial cell death. A method for preventing or reducing ischemia/reperfusion induced myocardial cell death in a human is provided as are methods for identifying pharmaceuticals which interfere with PUMA function. Also herein provided is a method for reducing stem cell death in stem cell explants wherein the explants are intended to restore cardiac efficiency following cell death in response to coronary infarct.Type: GrantFiled: August 8, 2007Date of Patent: May 4, 2010Assignee: Boston Biomedical Research InstituteInventors: Peter Erhardt, Ambrus Toth
-
Patent number: 7700299Abstract: The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.Type: GrantFiled: May 19, 2006Date of Patent: April 20, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Joachim Moecks, Andreas Strauss, Gerhard Zugmaier
-
Patent number: 7691373Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: January 5, 2007Date of Patent: April 6, 2010Assignee: Schering CorporationInventors: Jenny Valladeau, Odile Ravel, Elizabeth Esther Mary Bates, John Ford, Sem Saeland, Serge J. E. Lebecque
-
Patent number: 7687241Abstract: The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipetidyl peptidase IV (DPPIV)] expressed on the surface of metastasizing cancer cells.Type: GrantFiled: December 10, 2004Date of Patent: March 30, 2010Assignee: The Research Foundation of State University of New YorkInventor: Wen-Tien Chen
-
Patent number: 7682806Abstract: The invention relates to the use of Reelin as a marker for diagnosing psychiatric conditions. The disclosed tools and techniques can facilitate the diagnosis of psychiatric disorders including major depression, bipolar disorder, schizophrenia and autism.Type: GrantFiled: January 17, 2008Date of Patent: March 23, 2010Assignee: Regents of the University of MinnesotaInventor: S. Hossein Fatemi
-
Patent number: 7682805Abstract: The invention relates to the use of Reelin as a marker for diagnosing psychiatric conditions. The disclosed tools and techniques can facilitate the diagnosis of psychiatric disorders including major depression, bipolar disorder, schizophrenia and autism.Type: GrantFiled: January 17, 2008Date of Patent: March 23, 2010Assignee: Regents of the University of MinnesotaInventor: S. Hossein Fatemi
-
Patent number: 7678581Abstract: A tissue sample to be analyzed is tested. Multiple different samples of multiple areas of said tissue sample, each of said multiple areas is a smaller area than an entire tissue sample to be analyzed. After analysis, the tissue sample is processed in a way that facilitates viewing tumor information on the sample, for example, by fixing or staining. An area is identified on the stained sample, and at least one of the samples that corresponds to an identified area is tested. This small area is tested using a technique that homogenizes the sample before testing.Type: GrantFiled: January 28, 2008Date of Patent: March 16, 2010Assignee: Clarient, Inc.Inventor: Jose DeLa Torre Bueno
-
Patent number: 7666613Abstract: The present invention relates to neurotrypsin and to pharmaceutical and diagnostic compositions which comprise neurotrypsins and to compositions which effect neurotrypsin levels.Type: GrantFiled: May 12, 2004Date of Patent: February 23, 2010Assignee: Universitat ZürichInventor: Peter Sonderegger
-
Patent number: 7662642Abstract: Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.Type: GrantFiled: October 7, 2003Date of Patent: February 16, 2010Assignee: Wellstat BioCatalysis, LLCInventors: John H. Kenten, Alfonso Tramontano, Aprile L. Pilon, Gerald L. Lohnas, Steven F. Roberts
-
Patent number: 7655425Abstract: A chemokine receptor binds to MCP-1, MIP-1? and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1? and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.Type: GrantFiled: September 3, 2004Date of Patent: February 2, 2010Assignee: Glaxo Group LimitedInventors: Timothy N. C. Wells, Christine A. Power
-
Patent number: 7642064Abstract: The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.Type: GrantFiled: December 20, 2004Date of Patent: January 5, 2010Assignee: Ventana Medical Systems, Inc.Inventors: Christopher Bieniarz, Michael Farrell
-
Patent number: 7632652Abstract: The invention is directed to novel compositions of matter and methods of detecting in situ an immunohistochemical epitope or nucleic acid sequence of interest in a biological sample comprising binding an enzyme-labeled conjugate molecule to the epitope or sequence of interest in the presence of a redox-inactive reductive species and a soluble metal ion, thereby facilitating the reduction of the metal ion to a metal atom at or about the point where the enzyme is anchored. Novel phosphate derivatives of reducing agents are described that when exposed to a phosphatase are activated to their reducing form, thereby reducing metal ions to insoluble metal.Type: GrantFiled: June 24, 2004Date of Patent: December 15, 2009Assignee: Ventana Medical Systems, Inc.Inventors: Christopher Bieniarz, Casey A. Kernag, Jerome W. Kosmeder, Paula Rodgers, Jennifer Wong
-
Patent number: 7629138Abstract: An estrogen receptor gene and utilization of the estrogen receptor gene. The estrogen receptor gene contains a nucleotide sequence coding for any of the following amino acid sequences: (a) the amino acid sequence of SEQ ID NO:1, (b) the amino acid sequence of SEQ ID NO:4, (c) the amino acid sequence of SEQ ID NO:23, (d) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO:1, (e) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO:4, and (f) an amino acid sequence exhibiting 85% or more amino acid identity to the amino acid sequence of SEQ ID NO:23.Type: GrantFiled: June 27, 2008Date of Patent: December 8, 2009Assignee: Sumitomo Chemical Company LimitedInventor: Koichi Saito
-
Patent number: 7618791Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: October 6, 2006Date of Patent: November 17, 2009Assignee: ZymoGenetics, LLCInventor: Theodore E. Whitmore
-
Patent number: 7611853Abstract: Malarial parasite Plasmodium falciparum is responsible for the most severe form of malaria in humans, causing about 2 million deaths every year. Lack of effective vaccines and emergence of drug-resistant strains necessitate the need of novel drug targets to treat the disease. The present invention describes a novel assay method of identifying candidate compounds as anti-malarials based on the property of binding to plasmodial parasite 90 kDa heat shock protein.Type: GrantFiled: December 1, 2003Date of Patent: November 3, 2009Assignee: Indian Institute of ScienceInventors: Tatu Utpal, Pavithra Soundara Raghavan, Banumathy Gowrishankar
-
Patent number: 7608414Abstract: Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.Type: GrantFiled: February 8, 2006Date of Patent: October 27, 2009Assignee: Glycominds, LtdInventors: Nir Dotan, Avinoam Dukler, Rom T. Altstock
-
Patent number: 7608412Abstract: The p62 protein has been analyzed and identified as the significant contributor to several metabolic pathways that lead to metabolic syndrome, Alzheimer's Disease, and other related diseases. The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in blood insulin levels. The accumulation of tau protein and amyloid beta protein in neurological tissues is a hallmark of neurological metabolic diseases such as Alzheimer's Disease and related dementias. Moreover, increase blood insulin levels is an indicator of insulin resistance in mammals. Accordingly, the present invention provides a method for screening a mammal for metabolic disease comprising the step of detecting the absence of the p62 protein.Type: GrantFiled: October 5, 2006Date of Patent: October 27, 2009Assignee: Auburn UniversityInventors: Marie W. Wooten, Maria T. Diaz-Meco, Jorge Moscat
-
Patent number: 7604948Abstract: The present invention provides methods of identifying biomarkers indicative of the presence of a neurodevelopmental disorder, including an autism spectrum disorder, in an individual, using cytometry and mass spectrometry. The invention further provides methods of using the identified biomarkers to diagnose the presence of a neurodevelopmental disorder, including an autism spectrum disorder.Type: GrantFiled: May 5, 2006Date of Patent: October 20, 2009Assignee: The Regents of the University of CaliforniaInventors: David G. Amaral, Blythe A. Corbett
-
Patent number: 7598050Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.Type: GrantFiled: December 8, 2006Date of Patent: October 6, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
-
Patent number: 7595168Abstract: According to the present invention, there is provided a method of screening for a substance useful for transdifferentiation of microglia into neurons, a method of producing neurons, and a method of treating a neurologic disorder.Type: GrantFiled: September 14, 2006Date of Patent: September 29, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Tetsuhiro Niidome, Satoru Matsuda, Takeshi Kihara, Hachiro Sugimoto
-
Patent number: 7592150Abstract: Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.Type: GrantFiled: December 3, 2003Date of Patent: September 22, 2009Assignee: Glycominds, LtdInventors: Nir Dotan, Avinoam Dukler
-
Patent number: 7569675Abstract: A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage compared to currently available PR antibody. Furthermore, the very low background when the lagomorph derived monoclonal antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new PR antibody (clone SP2) antibody had favorable results when compared to mouse monoclonal antibody PR (clone 1A6), the best one in the current market. The PR antibody may prove of great value in the assessment of PR status in human breast cancer. Humanized versions of the PR antibody may provide therapeutic benefits.Type: GrantFiled: September 11, 2002Date of Patent: August 4, 2009Assignee: Spring Bioscience CorporationInventors: Haiying Xia, Zhida Huang
-
Patent number: 7565251Abstract: A method for fluorophore bias removal in microarray experiments in which the fluorophores used in microarray experiment pairs are reversed. Further, a method for calculating the individual errors associated with each measurement made in nominally repeated microarray experiments. This error measurement is optionally coupled with rank based methods in order to determine a probability that a cellular constituent is up or down regulated in response to a perturbation. Finally, a method for determining the confidence in the weighted average of the expression level of a cellular constituent in nominally repeated microarray experiments.Type: GrantFiled: December 12, 2005Date of Patent: July 21, 2009Assignee: Rosetta Inpharmatics LLCInventors: Roland Stoughton, Hongyue Dai
-
Patent number: 7547515Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: August 11, 2005Date of Patent: June 16, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Patent number: 7534579Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.Type: GrantFiled: November 18, 2005Date of Patent: May 19, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Maria Alexandra Glucksmann, Fong-Ying Tsai
-
Patent number: 7531314Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.Type: GrantFiled: August 4, 2006Date of Patent: May 12, 2009Assignee: University of WashingtonInventors: Grace A. Maresh, Alan D. Snow
-
Patent number: 7524639Abstract: A novel assay method suitable for screening of novel antipsychotics wherein the drugs may be selected based on the differential internalization of the 5-HT2A receptor in neuronal and non-neuronal cell lines effect for it to predict the extrapyramidal symptoms that may be induced by an antipsychotic without having to carry out in vivo experiments.Type: GrantFiled: April 17, 2006Date of Patent: April 28, 2009Assignee: Tata Institute of Fundamental ResearchInventors: Mitradas Madhav Panicker, Samarjit Bhattacharyya
-
Patent number: 7517663Abstract: The present invention relates to a rabbit monoclonal antibody that binds to human Id1 protein and/or mouse Id1 protein with high specificity and high affinity. The antibody has a binding constant, measured with respect to human Id1 protein and/or mouse Id1 protein, equal to or greater than 1×108/molar. The antibody has no substantial cross-reactivity with other family Id proteins such as Id2, Id3, or Id4, or other endogenous proteins present in the cells that express Id1 protein. The high specificity and high affinity of the rabbit monoclonal antibodies of the present invention allows sensitive and specific detection and/or quantitation of Id1 protein in biological samples. The antibodies are useful in immunochemical-based assays such as ELISA, western blot, and immunohistochemical staining.Type: GrantFiled: June 13, 2006Date of Patent: April 14, 2009Assignees: Biocheck, Inc., Angiogenex, Inc.Inventors: Jung-Shou Chen, William A. Garland
-
Patent number: 7517648Abstract: The present invention relates to Nephronophthisis, in particular to the NPHP5 protein (nephrocystin-5) and nucleic acids encoding the NPHP5 protein. The present invention also provides assays for the detection of NPHP5 polymorphisms and mutations associated with disease states.Type: GrantFiled: February 18, 2005Date of Patent: April 14, 2009Assignee: The Regents of the University of MichiganInventors: Friedhelm Hildebrandt, Edgar A. Otto, Hemant Khanna, Anand Swaroop
-
Patent number: 7517908Abstract: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.Type: GrantFiled: May 20, 2005Date of Patent: April 14, 2009Assignee: Duke UniversityInventors: Ranga R. Krishnan, Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinova, Tatiana D. Sotnikova
-
Patent number: 7510824Abstract: A method of screening peptides which bind to at least one PDZ domain and comprise a cell-membrane transduction domain for use in treating traumatic injury to the brain or spinal cord by deforming neurons on a flexible substrate with sublethal stretch, then inflicting a secondary injury, and determining survival of the stretched neurons in the absence or presence of the peptide which is being screened.Type: GrantFiled: August 31, 2004Date of Patent: March 31, 2009Assignee: NoNO Inc.Inventor: Michael Tymianski
-
Patent number: 7491499Abstract: The present invention provides a method for diagnosing or predicting susceptibility to a psychiatric disorder in an individual, which comprises confirming molecular diversity and/or subcellular distribution of DISC 1 in the cell from the individual. In addition, a novel risk haplotype of DISC1 for psychiatric disorder is also provided.Type: GrantFiled: January 28, 2005Date of Patent: February 17, 2009Assignees: The Johns Hopkins University, Rusk Intellectual Reserve AGInventor: Akira Sawa
-
Publication number: 20090024019Abstract: Methods and devices for detecting an analyte are provided. An analyte binding molecule is fixed to a nanoparticle to form a nanoparticle complex. The analyte binding molecule is capable of binding an analyte. The nanoparticle complex is introduced into one of a circulatory system of an animal or biological fluid of the animal. The analyte is allowed to bind to the nanoparticle complex. The analyte bound nanoparticle complex can be extracted and the presence of the analyte can be detected.Type: ApplicationFiled: July 17, 2008Publication date: January 22, 2009Inventors: Adam L. Stein, Jacob M. White
-
Publication number: 20090017471Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: ApplicationFiled: June 20, 2008Publication date: January 15, 2009Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7456027Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury, organ injury, and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.Type: GrantFiled: April 15, 2005Date of Patent: November 25, 2008Assignees: University of Florida Research Foundation, Inc., Banyan Biomarkers, Inc.Inventors: Kevin Ka-Wang Wang, Ronald Hayes, Ming Chen Liu, Monika Oli
-
Patent number: 7452681Abstract: The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.Type: GrantFiled: May 5, 2006Date of Patent: November 18, 2008Assignee: The Regents of the University of CaliforniaInventors: David G Amaral, Judy Van de Water
-
Patent number: 7445905Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: January 26, 2007Date of Patent: November 4, 2008Assignee: Genentech, Inc.Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
-
Patent number: 7442516Abstract: The present invention provides an antibody which specifically recognizes a CNS tau protein but not a peripheral tau protein. More specifically, the present invention provides an antibody obtainable by using a polypeptide comprising an amino acid sequence of a connective portion between the amino acid sequence encoded by Exon 4 of a gene encoding a tau protein and the amino acid sequence encoded by Exon 5 thereof as an epitope specific to the isoform of tau protein predominantly existing in central nervous tissues. The present invention further provides a method of detecting Alzheimer's disease and a reagent kit using the antibody.Type: GrantFiled: February 11, 2005Date of Patent: October 28, 2008Assignees: Mitsubishi Chemical Corporation, Mitsubishi Kagaku Iatron, Inc.Inventors: Hideto Ohno, Koichi Ishiguro, Masaki Imagawa
-
Patent number: 7429448Abstract: The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions.Type: GrantFiled: July 17, 2003Date of Patent: September 30, 2008Assignee: Institut PasteurInventors: Catherine Rougeot, Francois Rougeon
-
Publication number: 20080188641Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: May 1, 2007Publication date: August 7, 2008Applicant: University of California San DiegoInventor: Judith A. Varner
-
Patent number: 7405049Abstract: Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.Type: GrantFiled: April 15, 2003Date of Patent: July 29, 2008Assignee: B.R.A.H.M.S. AktiengesellschaftInventors: Andreas Bergmann, Christina Fischer-Schulz, Joachim Struck
-
Patent number: 7405051Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.Type: GrantFiled: October 31, 2001Date of Patent: July 29, 2008Assignee: Astellas Pharma Inc.Inventors: Jun Takasaki, Mitsuyuki Matsumoto, Masazumi Kamohara, Tetsu Saito, Takahide Ohishi, Takatoshi Soga
-
Patent number: 7396654Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.Type: GrantFiled: April 15, 2005Date of Patent: July 8, 2008Assignees: University of Florida Research Foundation, Inc., Banyan Biomarkers, Inc.Inventors: Ronald Hayes, Kevin Ka-Wang Wang, Ming Chen Liu, Monika Oli
-
Patent number: 7393945Abstract: An estrogen receptor gene and utilization of the estrogen gene are described. The estrogen receptor gene has a nucleotide sequence coding for any of the following amino acid sequences: (a) the amino acid sequence of SEQ ID NO: 1, (b) the amino acid sequence of SEQ ID NO: 4, (c) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO: 1, and (d) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO: 4.Type: GrantFiled: July 23, 2002Date of Patent: July 1, 2008Assignee: Sumitomo Chemical Company LimitedInventor: Koichi Saito
-
Patent number: 7384748Abstract: The present invention relates to the NTE proteins and nucleic acids encoding the NTE proteins. The present invention further provides assays for the detection of NTE polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NTE proteins.Type: GrantFiled: December 13, 2005Date of Patent: June 10, 2008Assignee: The Regents of the University of MichiganInventors: John K. Fink, Shirley Rainer